We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.09%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.09B
AUM Growth
-$133M
Cap. Flow
+$26.4M
Cap. Flow %
0.52%
Top 10 Hldgs %
35.29%
Holding
140
New
25
Increased
26
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$161M
2
BIIB icon
Biogen
BIIB
+$68.3M
3
BAX icon
Baxter International
BAX
+$66.2M
4
LLY icon
Eli Lilly
LLY
+$62.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$52.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$117M
2
PFE icon
Pfizer
PFE
+$71.4M
3
UNH icon
UnitedHealth
UNH
+$50.4M
4
NTRA icon
Natera
NTRA
+$46.7M
5
ETNB
89bio
ETNB
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Industrials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
101
X4 Pharmaceuticals
XFOR
$375M
$5.06M 0.1%
193,924
– –
VIGL
102
DELISTED
Vigil Neuroscience
VIGL
$4.39M 0.09%
448,891
– –
SRRK icon
103
Scholar Rock
SRRK
$5.95B
$4.12M 0.08%
515,000
-364,003
-41% -$3.69M
NXTC icon
104
NextCure
NXTC
$23.1M
$4.01M 0.08%
225,918
– –
SYBX
105
DELISTED
Synlogic
SYBX
$3.81M 0.07%
402,000
– –
CMMB
106
Chemomab Therapeutics
CMMB
$11.5M
$3.56M 0.07%
560,319
-84,225
-13% -$661K
EPIX
107
DELISTED
ESSA Pharma
EPIX
$3.56M 0.07%
1,198,337
+833,037
+228% +$2.45M
TARA icon
108
Protara Therapeutics
TARA
$218M
$2.48M 0.05%
793,558
-37,083
-4% -$123K
BOLT icon
109
Bolt Biotherapeutics
BOLT
$7.63M
$2.14M 0.04%
77,050
+38,497
+100% +$1.13M
AFIB
110
DELISTED
Acutus Medical Inc
AFIB
$2M 0.04%
2,648,386
– –
RVNC
111
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.61M 0.03%
+50,000
New +$1.56M
HRTX icon
112
Heron Therapeutics
HRTX
$93.7M
$1.21M 0.02%
+802,700
New +$2.01M
PHGE icon
113
BiomX
PHGE
$1.96M
$964K 0.02%
16,639
+1,831
+12% +$116K
MRSN
114
CALL
DELISTED
Mersana Therapeutics
MRSN
$866K 0.02%
+8,428
New +$1.18M
NKTR icon
115
Nektar Therapeutics
NKTR
$2.31B
$727K 0.01%
+68,937
New +$2.09M
OMIC
116
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$654K 0.01%
18,023
– –
SYRE icon
117
Spyre Therapeutics
SYRE
$8.28B
$521K 0.01%
71,889
– –
HARP
118
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$462K 0.01%
62,122
-89,528
-59% -$753K
ALT icon
119
CALL
Altimmune
ALT
$572M
$422K 0.01%
+100,000
New +$1.19M
NKTR icon
120
CALL
Nektar Therapeutics
NKTR
$2.31B
$383K 0.01%
+36,333
New +$1.1M
ALT icon
121
Altimmune
ALT
$572M
$214K ﹤0.01%
+50,600
New +$601K
ACRS icon
122
Aclaris Therapeutics
ACRS
$723M
– –
-2,758,434
Closed -$43.4M
AMRX icon
123
Amneal Pharmaceuticals
AMRX
$6.09B
– –
-1,583,490
Closed -$3.15M
APLT
124
DELISTED
Applied Therapeutics
APLT
– –
-3,050,921
Closed -$2.32M
BNTX icon
125
BioNTech
BNTX
$23.4B
– –
-36,300
Closed -$5.45M
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2023 Portfolio in Review

As of Q1 2023, OrbiMed held 140 positions worth $5.09B, down 2.6% from $5.23B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q1 2023 filing shows 25 new, 26 increased, 29 reduced and 16 closed positions. Its largest new stake was Baxter International: 1,562,000 shares worth $63.4M. The largest sale was Seagen Inc. Common Stock, an estimated $117M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q1 2023 buy was Baxter International: 1,562,000 shares worth $63.4M.
  • OrbiMed added most to Enliven Therapeutics in Q1 2023, an estimated $161M increase.
  • OrbiMed's biggest Q1 2023 reduction was UnitedHealth, cutting an estimated $50.4M.
  • OrbiMed fully exited Seagen Inc. Common Stock in Q1 2023, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 35% of its $5.09B portfolio in Q1 2023.
  • OrbiMed opened 25 new positions and closed 16 in Q1 2023.
  • OrbiMed's portfolio value fell 2.6% quarter-over-quarter to $5.09B.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.